Lead Product(s) : Cadonilimab,Fluoropyrimidine,Capecitabine
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Akeso’s Cadonilimab Receives Second Approval For Gastric/GEJ Cancer
Details : Cadonilimab, a novel bispecific antibody targets PD-1 and CTLA-4 has been approved in combination with chemotherapy for locally advanced unresectable or metastatic G/GEJ adenocarcinoma.
Brand Name : AK104
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 30, 2024
Lead Product(s) : Cadonilimab,Fluoropyrimidine,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tislelizumab,Carboplatin,Fluoropyrimidine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
BeiGene’s TEVIMBRA® BLA Accepted for Gastric Cancer
Details : Tevimbra (tislelizumab) is a humanized IgG4 anti-PD-1 monoclonal antibody being evaluated for first-line treatment of gastric or gastroesophageal junction cancers.
Brand Name : Tevimbra
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 27, 2024
Lead Product(s) : Tislelizumab,Carboplatin,Fluoropyrimidine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tislelizumab,Fluoropyrimidine
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
Details : BGB-A317 (tislelizumab) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fcγ receptors on macrophages, helping to aid the body’s immune cells to detect and fight tumors.
Brand Name : BGB-A317
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 24, 2023
Lead Product(s) : Tislelizumab,Fluoropyrimidine
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bevacizumab,Fluoropyrimidine,Irinotecan Hydrochloride
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Etana
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Bevagen®(Bevacizumab) is biosimilar of the recombinant humanized anti-VEGF monoclonal antibody bevacizumab. Vascular endothelial growth factor (VEGF) is a critical factor in promoting angiogenesis, and is highly expressed by the endothelial cells in mos...
Brand Name : Bevagen
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 14, 2022
Lead Product(s) : Bevacizumab,Fluoropyrimidine,Irinotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Etana
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nivolumab,Fluoropyrimidine
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The approvals are based on the Phase 3 trial, which evaluated Opdivo (Nivolumab) in combination with chemotherapy (n=321) and Opdivo plus Yervoy (n=325) each compared to chemotherapy alone (n=324), and was the largest Phase 3 trial of an immunotherapy in...
Brand Name : Opdivo
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 27, 2022
Lead Product(s) : Nivolumab,Fluoropyrimidine
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pembrolizumab,Fluoropyrimidine,Oxaliplatin
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The CHMP’s recommendation was based on results from Phase 2 KEYNOTE-158 trial as well as results from Phase 2 KEYNOTE-164 trial, both of which supported U.S.FDA accelerated approval of KEYTRUDA as cancer treatment approved based on a biomarker in MSI-H...
Brand Name : Keytruda
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 25, 2022
Lead Product(s) : Pembrolizumab,Fluoropyrimidine,Oxaliplatin
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pembrolizumab,Fluoropyrimidine,Platinum
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Merck Provides Update on KEYTRUDA® (Pembrolizumab) Indication in Third-Line Gastric Cancer in the US
Details : KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Brand Name : Keytruda
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 01, 2021
Lead Product(s) : Pembrolizumab,Fluoropyrimidine,Platinum
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pembrolizumab,Fluoropyrimidine,Platinum
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.
Brand Name : Keytruda
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 24, 2021
Lead Product(s) : Pembrolizumab,Fluoropyrimidine,Platinum
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?